

NewCo Licensing






Last update: 2024/12

Antibodies Small A	Aolecules ADCs Re	ecomb Prote
Target	Indications	Preclini
LAG3	solid tumors and lymphoma; autoimmur	ne Carlos
EGFR; CD3	metastatic breast cancer; gastric canc	er
Enzyme-controlled TAA; CD3	solid tumors	
CD19; CD3; CD28	B-cell malignant hematological tumors; autoi diseases including SLE, RA, Myasthenia grav	
IL-2 prodrug	solid tumors	
ROR1; CD3	lymphoma; breast cancer	
TAA; CD3	hepatocellular carcinoma	
PD-1/IL-15 cytokine antibody conjudgat	e solid tumors	
CD3 bispecific antibody prodrug	solid tumors	
HER2; Trop2	breast cancer; cervical cancer; gastric co	incer
PD-L1; VEGF	lung cancer; breast cancer	

tein



inical Ph I Ph II Ph III Commercial




Antibodies Small	Nolecules AE	DCs	Recom	o Protein
Target	Indico	ations		Preclinical
KV1.3 (Topical)	atopic de	rmatitis		
сМус	pancreatio	cancer		
PI3K-mTOR-Akt pathway	melanoma; esophageal cc	ancer, colore	ectal cancer	
mTORC2	neuroendocrine tumors; lu	ıng cancer;	breast cancer	
FXIa	throm	bus		
KV1.3 (Oral)	inflammatory b	owel diseas	e	
сМус	gynecologic	al tumors:		

otein



linical PhI PhII PhIII Commercial







Small Molecules Antibodies **ADCs** Recomb Protein **B** Preclinical Ph I Ph II Ph III Commercial Indications Target Nectin-4/Trop2 bladder cancer; cervical cancer; lung cancer pancreatic cancer; lung cancer; cMet/HER2 gastrointestinal

cancer; renal cancer



Antibodies	Small Molecules	ADCs	Recomb Prot
Entity	ý	Indications	Preclir
Human II-	_11	ombocytopenia caus iotherapy or chemoth	
Reteplas	se ac	cute myocardial infar	ction
Human EF	Human EPO anemia caused by CKD		KD





linical Ph I Ph II Ph III Commercial



Meeting Request

Join us in bridging the gap between Chinese pharmaceutical innovation and global markets. Contact our NewCo team today to explore how we can unlock new possibilities together.

- bd@unibestcn.com
- +86 (0)574 2785 5666
- +86 152 5057 3086

